Comparative Assessment of Serum versus Menstrual Blood for Diagnostic Purposes: A Pilot Study

Background: Blood testing remains an essential component of diagnosis and prevention of disease. Phlebotomists, Laboratory Infrastructure, Storage, Collection, and Transport are required for Current Methods of Blood Collection. Menstrual Blood has many similar characteristics to circulating blood but has not previously been assessed as a Potential Diagnostic Resource. Objective: To assess if biomarkers derived from menstrual blood correlate with systemic blood. Study design: This was a prospective, observational pilot study of healthy reproductive-aged women. We chose a panel of 9 Biomarkers, used in preventative health assessments and for following clinical conditions, and compared systemic and menstrual blood levels. Results: Eighty-Four volunteers were screened over two months; 35 provided a menstrual and serum sample, of which 20 had a sample adequate for analysis. Overall, the correlation was observed, particularly for 7 Biomarkers, with no statistically significant differences between the mean menstrual and serum values. These include cholesterol (P for differences in means=0.89, R2 for correlation=0.89), Creatinine (P=0.32, R2=0.94), HSCRP (P=0.89, R2=0.99), LDL (P=0.21, R2=0.84), Triglycerides (P=0.45, R2=0.89), Hba1c (P=0.54, R2=0.80), and HDL (P=0.33, R2=0.77). One biomarker, FSH (P<0.001, R2=0.97), was less directly comparable to systemic blood, but a linear relationship was recognized suggesting that the correlation could be mathematically derived, and therefore diagnostic utility is possible. Conclusion: Based on our results, menstrual blood can reliably estimate levels of several biomarkers and may be a promising option for noninvasive collection of blood for diagnosis and health monitoring. Larger trials are needed to confirm these findings. of disorders were present in menstrual fluid [1]. These disorders include endometriosis, breast, Cervical, Ovarian and Endometrial Cancer. Several other studies have detected the presence of Human Papilloma Virus (HPV) in menstrual blood implying that it may be useful for non-invasive screening for cervical cancer or pre-cancer [2,3]. Furthermore, menstrual blood has been studied for screening or diagnosis of Sexually Transmitted Infections (STIS). Alary M, et al. explored the potential of using vaginal fluid collected in menstrual pads for Chlamydia detection. This proved to have sensitivity and specificity equivalent to, or even higher than, existing methods, including vaginal swabs or urine samples [4]. These data combine to provide support for the potential utility of menstrual blood-based testing as a non-invasive alternative blood source for diagnostic or therapeutic analysis. Despite this apparent potential, menstrual blood remains a relatively uninvestigated area for diagnostics; no published literature explores the correlation of systemic versus menstrual-based blood for assessing biomarkers relative to indicators of health or disease. Introduction Whole blood or Serum (Systemic Blood) is commonly used to diagnose or monitor many medical conditions. However, obtaining a specimen is an invasive procedure, requiring medical assistance. It can be inconvenient, costly, painful, and anxiety-provoking. Most reproductive-aged women menstruate regularly, and while menstrual blood shares many characteristics with systemic blood, it has not been subject to rigorous clinical investigations for diagnostic and therapeutic purposes. Menstrual blood is composed of three distinct body fluids: whole blood, vaginal fluid, and the cells and fluid of the late Secretory Phase of the endometrial lining and the cervix, shed during menstruation. Molecular proteomic studies have shown considerable correlation with systemic blood; however, menstrual blood also contains additional fluids [1]. Specifically, at least 385 additional proteins can be detected in menstrual blood when compared with systemic blood [1]. In 2012 Siegel D, et al. first defined the proteomics of menstrual blood, and found that several biomarkers for a wide range Sci Forschen O p e n H U B f o r S c i e n t i f i c R e s e a r c h Citation: Naseri S, Lerma K, Blumenthal PD (2019) Comparative Assessment of Serum versus Menstrual Blood for Diagnostic Purposes: A Pilot Study. J Clin Lab Med 4(2): dx.doi. org/10.16966/2572-9578.130 2 Journal of Clinical and Laboratory Medicine Open Access Journal To assess this, we conducted a proof-of-concept study, comparing menstrual blood to systemic blood. We hypothesized that if menstrual blood biomarkers correlated with systemic blood, this alternative testing method could have potential as a convenient, non-invasive and cost-effective approach to blood analysis for both diagnosis and therapeutics. If found reliable, such an approach could enhance opportunities for early disease detection and regular health monitoring among women who menstruate. Materials and Methods This was a prospective, observational, pilot study of healthy reproductive-aged women. Interested women completed a telephone screening to assess eligibility and willingness to participate. Exclusion criteria included being younger than 18 years of age, older than 45 years, postmenopausal, not menstruating regularly, and uncomfortable with or clinically unable to use a menstrual cup for menstrual blood collection. Those who were eligible per telephone screening were invited to an in-person meeting. During the meeting the study processes were explained in detail and instructions of how to use a menstrual cup were given to ensure participants were aware and comfortable using it for the menstrual blood collection. Demographic and other information such as age, weight, birth control usage, expected dates for menstruation, and health issues and concerns, were collected. All participants signed consent forms and were given a study kit containing a menstrual cup and two blood collection tubes. The menstrual cup (diva international inc., on, Canada) used for menstrual blood collection is a flexible menstrual cup that is worn internally, around the cervix to collect, rather than absorb, menstrual flow. It is hypo-allergenic, latex-free and safe when used as directed. The materials used in the study are commonly used and are FDA, CE or who-prequalified. The study was approved by the Stanford Institutional Review Board (IRB-35817). Participants were instructed to contact study staff on the first day of their period, being the first day with actual flow. That day, participants were instructed to stop intake of food after midnight. On the second day of their period participants were instructed to use the menstrual cup for three hours, starting at the time they woke up in the morning, and then immediately pour the collected menstrual blood into the designated blood collection tubes. The second day was chosen due to convenience and because the second day of menstruation for most participants was found to be the day with the heaviest flow of menstrual blood. When participants presented at the study site-a venous blood draw was performed, and the menstrual blood samples were collected. The venous samples were collected on the same day as the menstrual blood samples. Neither the participants nor study staff observed any clotting in the menstrual blood samples. Both blood samples were pipetted onto Dried Blood-Spot (DBS) blood collection cards (advance DX inc., AZ, USA). DBS is considered interchangeable with venepuncture [5,6] and was used as a convenient and costeffective way to transport blood samples to the laboratory for analysis. Because both samples were collected on DBS and both samples were analyzed with same methods and by the same laboratory, any effect on the samples using DBS would be applicable to both samples and therefore the comparison of the two samples is valid. A total of four cards per sample type were utilized. The eight blood collection cards per participant were shipped on the same day to a CLIA/CAP Certified Laboratory and DBS specialist, us specialty (San Diego, CA, USA), where the coded samples were analyzed. All samples were provided to the lab with no indication as to the source (i.e., menstrual or serum), so that analyses were performed in a “blinded” fashion. All participants were compensated for their travel and time spent in clinic. Results were analyzed using paired t-tests to compare mean values of systemic blood to menstrual blood; confidence intervals were calculated to provide insight into the magnitude of the mean differences. Further, via correlation analysis of the paired samples, we analyzed whether it is possible to predict systemic blood results based on menstrual blood results. We used the method of least squares to create the trend line. Such a calculation would mean that systemic blood values are not necessarily identical to menstrual blood results, but that correlations could be mathematically predicted, indicating that certain systemic blood biomarkers can be estimated from menstrual blood. To assess the strength of the linear relationship we used Pearson correlation coefficient, which varies from -1 (perfect linear negative relationship) to +1 (perfect linear positive relationship) with values around 0 corresponding to weak relationship.